Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

被引：15

作者：

Passaro, Antonio ^{[1
]}

Alesini, Daniele ^{[1
]}

Pochesci, Alessia ^{[1
]}

Cortesi, Enrico ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Div Med Oncol, I-00161 Rome, Italy

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2014年 / 14卷 / 05期

关键词：

EGFR; elderly; erlotinib; gefitinib; non-small-cell lung cancer; tyrosine kinase inhibitor; RECEPTOR TYROSINE KINASE; CHEMOTHERAPY-NAIVE PATIENTS; PHASE-II TRIAL; INHIBITOR; PHARMACOKINETICS; COMBINATION; SORAFENIB; SAFETY; GEMCITABINE; VINORELBINE;

D O I：

10.2174/187152061405140501101624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non- small- cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co- morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non- randomised clinical trials.

引用

页码：646 / 650

页数：5

共 41 条

[1] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].

Alroy, I ;

Yarden, Y .

FEBS LETTERS, 1997, 410 (01) :83-86

[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[3] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) [J].

Bearz, Alessandra ;

Fratino, Lucia ;

Spazzapan, Simon ;

Berretta, Massimiliano ;

Giacalone, Annalisa ;

Simonelli, Cecilia ;

Tirelli, Umberto .

LUNG CANCER, 2007, 55 (01) :125-127

[4] Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC) [J].

Borghaei, H. ;

Mehra, R. ;

Millenson, M. M. ;

Tuttle, H. ;

Ruth, K. ;

Magdalinski, A. J. ;

Mintzer, D. M. ;

Lee, J. W. ;

Simon, G. R. ;

Langer, C. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[5] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) [J].

Cappuzzo, F ;

Bartolini, S ;

Ceresoli, GL ;

Tamberi, S ;

Spreafico, A ;

Lombardo, L ;

Gregorc, V ;

Toschi, L ;

Calandri, C ;

Villa, E ;

Crinò, L .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :82-86

[6] Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib [J].

Carey, Kendall D. ;

Garton, Andrew J. ;

Romero, Maria S. ;

Kahler, Jennifer ;

Thomson, Stuart ;

Ross, Sarajane ;

Park, Frances ;

Haley, John D. ;

Gibson, Neil ;

Sliwkowski, Mark X. .

CANCER RESEARCH, 2006, 66 (16) :8163-8171

[7] Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older [J].

Chen, Yuh-Min ;

Tsai, Chun-Ming ;

Fan, Wen-Chien ;

Shih, Jen-Fu ;

Liu, Shih-Hao ;

Wu, Chieh-Hung ;

Chou, Teh-Ying ;

Lee, Yu-Chin ;

Perng, Reury-Perng ;

Whang-Peng, Jacqueline .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) :412-418

[8] Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations [J].

Costa, Daniel B. ;

Schumer, Susan T. ;

Tenen, Daniel G. ;

Kobayashi, Susumu .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1182-1184

[9] Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study [J].

Crino, Lucio ;

Cappuzzo, Federico ;

Zatloukal, Petr ;

Reck, Martin ;

Pesek, Milos ;

Thompson, Joyce C. ;

Ford, Hugo E. R. ;

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Ghiorghiu, Serban ;

Duffield, Emma L. ;

Armour, Alison A. ;

Speake, Georgina ;

Cullen, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4253-4260

[10] Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors [J].

Duran, Ignacio ;

Hotte, Sebastien J. ;

Hirte, Holger ;

Chen, Eric X. ;

MacLean, Martha ;

Turner, Sandra ;

Duan, Lixia ;

Pond, Gregory R. ;

Lathia, Chetan ;

Walsh, Scott ;

Wright, John J. ;

Dancey, Janet ;

Siu, Lillian L. .

CLINICAL CANCER RESEARCH, 2007, 13 (16) :4849-4857

← 1 2 3 4 5 →